US Stock Market Movement: Mirum surges on October 9 as AZURE-1 meets criteria and receives FDA approval

Mirum October 9th Surge Interpretation

Keywords: AZURE-1 Achieved, FDA Approval

1. On September 28, the company announced that the AZURE-1 Phase III study of breলovitug met the primary endpoint at week 24 in both dosing groups. Data from week 48 in the Phase II study showed deeper viral suppression and a higher rate of ALT normalization, with no new safety signals observed. The company plans to submit a BLA application in the first half of 2027.

2. On September 25, the company and Incyte announced that Atebrioz received approval from the U.S. FDA to reduce new heterotopic ossification volume in FOP patients aged 12 and above. The drug is expected to launch in the U.S. in October, and Mirum holds the global development and commercialization rights.

3. On October 8, RBC Capital Markets raised Mirum's target price from $135 to $155 and maintained its “Outperform” rating.

(Disclaimer: This content is generated by AI technology summarizing publicly available information and is for reference only. It does not constitute investment advice.)